- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ovarian, fallopian tube or primary peritoneal cancer
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Olaparib – November 2019
Olaparib: Tablet 100 mg, Tablet 150 mg ; Lynparza®
Last updated
20 March 2020